From Minor Excipient To Major Industry: China's Sodium Sulfobutyl Ether Β-Cyclodextrin Accelerates Entry into The Global Pharmaceutical Supply Chain

Sodium sulfobutyl ether β-cyclodextrin (SBE-β-CD) is an anionic, highly water-soluble cyclodextrin derivative and a key excipient for overcoming solubility challenges in injectable formulations. For years, its core supply has been dominated by a few overseas companies. However, in recent years, as Chinese manufacturers have made continuous breakthroughs in purification technology and quality systems, domestically produced SBE-β-CD is rapidly gaining entry into the global mainstream pharmaceutical supply chain.

International certifications are being achieved consecutively.  Binzhou Zhiyuan Biotech successfully obtained the CEP certification, further expanding China’s presence in the international arena.

Domestic regulatory access is accelerating simultaneously. Several other companies have completed CDE registration and synchronized DMF filings with the U.S., establishing a comprehensive "China-U.S.-EU" tripartite registration capability. During the COVID-19 pandemic, this excipient served as a critical component in remdesivir formulation, helping stabilize the global supply chain.

The market potential is vast. Industry data indicates that the global SBE-β-CD market reached approximately $52.39 million in 2025, with an expected annual compound growth rate exceeding 6%, projected to approach $100 million by 2034. The product is now included in the pharmacopoeias of China, the United States, and Europe. Leveraging abundant starch resources and strong chemical industry infrastructure, China has become the world’s primary hub for cyclodextrin production.

From import dependency to self-reliant supply and then to successful penetration into European and American markets, the evolution of China’s sodium sulfobutyl ether β-cyclodextrin reflects the broader transformation of China’s pharmaceutical excipients—from follower to peer and leader.